Ribociclib

Major

Ribociclib Clindamycin Topical C/T/S® Increased exposure of CYP3A4 substrate and an increased risk of CYP3A4 substrate-related adverse reactions Details Ribociclib Clindamycin Vaginal Cleocin Increased exposure of CYP3A4 substrate and an increased risk of CYP3A4 substrate-related adverse reactions Details Ribociclib Cobimetinib Cotellic Increased exposure of CYP3A4 substrate and an increased risk of CYP3A4 substrate-related adverse reactions Details Ribociclib Cyclosporine Injection Atopica Increased exposure of CYP3A4 substrate and an increased risk of CYP3A4 substrate-related adverse reactions Details Ribociclib Cyclosporine Ophthalmic Cequa Increased exposure of CYP3A4 substrate and an increased risk of CYP3A4 substrate-related adverse reactions Details Ribociclib Dasatinib Phyrago Increased dasatinib exposure and an increased risk of QT interval prolongation Details Ribociclib Deflazacort Emflaza Increased exposure to active metabolite of deflazacort Details Ribociclib Degarelix Injection Firmagon Increased risk of QT interval prolongation Details Ribociclib Deutetrabenazine Austedo An increased risk of QT interval prolongation Details Ribociclib Dexamethasone Injection Decadron Increased dexAMETHasone exposure Details Ribociclib Dexamethasone Ophthalmic Dexacidin® (as a combination product containing Dexamethasone, Neomycin, Polymyxin B) Increased dexAMETHasone exposure Details Ribociclib Disopyramide Norpace An increased risk of QT interval prolongation Details Ribociclib Docetaxel Beizray Increased DOCEtaxel exposure Details Ribociclib Docetaxel Injection Beizray Increased DOCEtaxel exposure Details Ribociclib Dofetilide Tikosyn Increased CYP3A4 substrates exposure, an increased risk of CYP3A4 substrate-related adverse reactions and an increased risk of QT... Details Ribociclib Dolasetron Anzemet An increased risk of QT interval prolongation Details Ribociclib Dolasetron Injection Anzemet An increased risk of QT interval prolongation Details Ribociclib Doxorubicin Adriamycin Increased doxorubicin exposure and an increased risk of doxorubicin-related adverse reactions Details Ribociclib Elacestrant Orserdu Increased elacestrant exposure and an increased risk of elacestrant-related adverse effects Details Ribociclib Enasidenib Idhifa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Ribociclib Encorafenib Braftovi Increased encorafenib exposure, an increased risk of encorafenib-related adverse reactions and an increased risk of QT interval pr... Details Ribociclib Entrectinib Rozlytrek Increased entrectinib exposure, increased frequency or severity of adverse reactions including increased risk of cardiac arrhythmi... Details Ribociclib Erdafitinib Balversa Increased erdafitinib exposure Details Ribociclib Eribulin Injection Halaven An increased risk of QT interval prolongation Details Ribociclib Erlotinib Tarceva Increased erlotinib exposure and risk of toxicity Details Ribociclib Everolimus Afinitor Increased exposure of CYP3A4 substrate and an increased risk of CYP3A4 substrate-related adverse reactions Details Ribociclib Famotidine Calmicid An increased risk of QT interval prolongation Details Ribociclib Famotidine Injection Calmicid An increased risk of QT interval prolongation Details Ribociclib Felbamate Felbatol An increased risk of QT interval prolongation Details Ribociclib Fentanyl Transdermal Patch Duragesic® Increased exposure of CYP3A4 substrate and an increased risk of CYP3A4 substrate-related adverse reactions Details Ribociclib Flecainide Tambocor® An increased risk of QT interval prolongation Details Ribociclib Foscarnet Injection Foscavir An increased risk of QT interval prolongation Details Ribociclib Fostemsavir Rukobia Increased risk of torsade de pointes Details Ribociclib Futibatinib Lytgobi Increased futibatinib exposure and increased risk of futibatinib-related adverse reactions Details Ribociclib Galantamine Razadyne An increased risk of QT interval prolongation Details Ribociclib Gatifloxacin Ophthalmic Zymar® An increased risk of QT interval prolongation Details Ribociclib Gemifloxacin Factive An increased risk of QT interval prolongation Details Ribociclib Gilteritinib Xospata Increased gilteritinib plasma concentrations Details Ribociclib Glasdegib Daurismo Increased risk of QT interval prolongation Details Ribociclib Goserelin Implant Zoladex Increased risk of QT interval prolongation Details